Monitor for first patient dosing announcement and additional regulatory approvals (Germany). Given the company's $2M market cap and history of sharp post-news declines, traders should consider high volatility risk and limited liquidity.
Price Chart
Executive Summary
Silexion Therapeutics announced initiation of GMP manufacturing of SIL204 with Catalent and ethics committee approval for its Phase 2/3 trial in locally advanced pancreatic cancer, advancing clinical readiness. The stock has a $2M market cap and historically poor post-announcement performance, indicating high risk despite this positive milestone.
Key Facts
- Initiated GMP clinical batch manufacturing of SIL204 with Catalent at its Limoges, France facility.
- Received Helsinki Ethics Committee approval from Tel Aviv Sourasky Medical Center for planned Phase 2/3 trial.
- Drug substance manufactured in 2025; drug product now in production with Catalent.
- Phase 2/3 trial will evaluate SIL204 in combination with standard-of-care chemotherapy via dual-route administration.
- Israeli Ministry of Health previously approved the trial; CTA submitted in Germany.
Financial Impact
Pre-revenue; no financial data disclosed.
Risk Factors
- Clinical trial failure or delays in patient enrollment.
- Need for additional capital to fund operations; potential dilution.
- Nasdaq listing compliance risk given low market cap.
- Historical poor stock performance post-positive announcements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293916 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1664 (−8.19%) |
Oct 5, 2026 21d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1664 (+36.68%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1664 (−39.93%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1664 (+39.99%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 | awaiting T+20 | — | $0.1664 (+47.67%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 | awaiting T+20 | — | $0.1664 (+47.74%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1664 (−33.01%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1664 (−33.01%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1664 (+33.01%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1664 (+60.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers